Barclays has initiated coverage on Cardinal Health Inc (CAH) with an Overweight rating, marking the firm’s first assessment of the company’s investment potential. This decision underscores Barclays' confidence in Cardinal Health's business model and growth prospects within the healthcare sector.
Headquartered in Dublin, Ohio, Cardinal Health is a major player in healthcare services and products, employing approximately 57,700 individuals. The company provides customized solutions for a range of healthcare facilities, including hospitals, pharmacies, and clinical laboratories. Its operations are divided into two main segments: Pharmaceutical and Specialty Solutions, which distributes a variety of pharmaceuticals, and Global Medical Products and Distribution (GMPD), which manufactures and distributes medical products.
As of December 9, 2025, Cardinal Health's stock is priced at $198.57, with a market capitalization of $47.5 billion. The company has a P/E ratio of 29.75 and a trailing twelve months (TTM) EPS of 6.63. Additionally, it offers a dividend yield of 102.7%.
Looking ahead, Cardinal Health is scheduled to report its next earnings on August 10, 2026, with an estimated EPS of $2.32 and revenue projections of $66.8 billion. This follows a strong performance in Q1 2026, where the company reported an EPS of $2.55, surpassing the estimate of $2.20 by 15.9%.
Analyst ratings, including Barclays' recent upgrade, can provide valuable insights but should be considered alongside a broader analysis of company fundamentals and market conditions. As of December 1, 2025, the consensus among analysts reflects a Buy rating, with 6 Strong Buy, 11 Buy, and 4 Hold ratings among a total of 21 analysts.